Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bullish
15 minStrong Bullish
5 minStrong Bearish
Daily trend turns up above $9.44
Key levels
Resistance$8.24
Resistance$6.46
Latest news & SEC filings
NewsAgomAb Therapeutics NV Files Form 4
SEC FilingAgomAb Therapeutics NV filed an insider trading report (Form 4)
NewsAgomAb Therapeutics NV Discloses Insider Buying
All AGMB news →AgomAb Therapeutics works on medicines for long-term inflammatory and scarring diseases. Its lead drug, ontunisertib, is taken by mouth and is being studied in fibrostenosing Crohn's disease, while AGMB-447 is inhaled and aimed at idiopathic pulmonary fibrosis. An earlier-stage antibody targets liver cirrhosis. The company is based in Antwerp, Belgium, with research operations in Spain and an office in Cambridge, Massachusetts.
Based on the company's 20-F filed Apr 23, 2026.
Nasdaq · Healthcare
SEPT Low Target
$34.00
SEPT Mid Target
$47.50
SEPT High Target
$60.00
Analyst Consensus
$47.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AGMB.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$47.50
0
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
Insider Signal
BUYING
9 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Epstein David R | director | Buy | 5,000 | $34K | Nov 5, 2026 |
| Epstein David R | director | Buy | 5,000 | $44K | Oct 21, 2026 |
| Epstein David R | director | Buy | 5,000 | $45K | Oct 8, 2026 |
| Epstein David R | director | Buy | 5,000 | $44K | Oct 6, 2026 |
| Knotnerus Tim Jasper | director officer | Buy | 5,000 | $44K | Oct 6, 2026 |
| Kemula Pierre Thadee Victor | officer | Buy | 3,000 | $26K | Oct 6, 2026 |
| Kemula Pierre Thadee Victor | officer | Buy | 5,000 | $43K | Oct 6, 2026 |
| Kemula Pierre Thadee Victor | officer | Buy | 2,000 | $17K | Oct 6, 2026 |
| Epstein David R | director | Buy | 5,000 | $43K | Oct 5, 2026 |
| Knotnerus Tim Jasper | director officer | Buy | 6,000 | $51K | Oct 5, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for AGMB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:07:15 | $6.17 | 1,579 | $$10K | BUY |
| 19:06:01 | $6.02 | 2,600 | $$16K | SELL |
| 19:06:01 | $6.02 | 2,000 | $$12K | SELL |
| 16:58:16 | $5.90 | 1,000 | $$6K | SELL |
| 16:58:06 | $5.90 | 1,000 | $$6K | SELL |
5 dark pool trades shown · $$49K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for AgomAb Therapeutics NV (AGMB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AgomAb Therapeutics NV (AGMB) is at $6.36, up 0.00% (+$0.00) at the Nov 13, 2026 close.
Latest AGMB news — Nov 6, 2026: AgomAb Therapeutics NV Files Form 4 · Nov 6, 2026: AgomAb Therapeutics NV filed an insider trading report (Form 4)
The average analyst price target for AGMB is $47.50, ranging from $34 to $60, based on 4 analysts. Latest: AgomAb Therapeutics upgrade on Aug 25, 2026.
Analyst ratings for AGMB: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
AGMB last reported on Aug 6, 2026: EPS -$0.91 vs $1.18 expected — a miss of 177.4%.
Resistance: $6.46, $8.24, $9.44.
Insider activity: BUYING, 9 buys and 0 sells in the last 90 days.
Nov 6, 2026: AgomAb Therapeutics NV Files Form 4 · Nov 6, 2026: AgomAb Therapeutics NV filed an insider trading report (Form 4) · Oct 23, 2026: AgomAb Therapeutics NV Discloses Insider Buying